Schlusskurs
Andere Börsenplätze
|
||
- USD | - |
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Michael Cullen
FOU | Founder | 78 | 21.09.11 |
Jennifer Simpson
CEO | Chief Executive Officer | 55 | 16.07.20 |
Susan Horvath
DFI | Director of Finance/CFO | 65 | 17.04.18 |
Tammy Groene
COO | Chief Operating Officer | - | 01.04.12 |
Chief Tech/Sci/R&D Officer | - | 01.06.22 | |
Rachel Bragg
PRN | Corporate Officer/Principal | - | 01.06.21 |
- | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Jennifer Simpson
CEO | Chief Executive Officer | 55 | 16.07.20 |
Director/Board Member | 63 | 30.09.15 | |
Michael Cullen
FOU | Founder | 78 | 21.09.11 |
Jeffrey Jacob
BRD | Director/Board Member | 62 | 15.06.22 |
Arthur Fratamico
BRD | Director/Board Member | 58 | 16.12.19 |
Dan Donovan
BRD | Director/Board Member | 59 | 15.06.22 |
Donald Schemel
BRD | Director/Board Member | 68 | 04.09.15 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 4 854 931 | 4 854 791 ( 100,00 %) | 70 ( 0,001442 %) | 100,00 % |
Unternehmenskontakt
Panbela Therapeutics, Inc.
712 Vista Boulevard Suite 305
55387, Waconia
+952 479 1196
http://www.panbela.com% 1. Jan. | Kap. | |
---|---|---|
+14,12 % | 3.161 Mrd. | |
+11,07 % | 87,62 Mrd. | |
+6,62 % | 79,59 Mrd. | |
-12,92 % | 54,14 Mrd. | |
+23,68 % | 48,15 Mrd. | |
+32,99 % | 47,69 Mrd. | |
-25,14 % | 46,81 Mrd. | |
+81,26 % | 42 Mrd. | |
-5,88 % | 25,77 Mrd. |